NAFLD as a continuous driver in the whole spectrum of vascular disease

Li, Wei; Liu, Jiayi; Cai, Jingjing; Zhang, Xiaojing; Zhang, Peng; She, Zhi‐Gang; Chen, Shaoze; Li, Hongliang

doi:10.1016/j.yjmcc.2021.10.007

Cited by 23 publications

(15 citation statements)

References 173 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…According to our recent meta-analysis, the estimated prevalence of NAFLD was 29.2% in China (3). The devastating complications of NAFLD are not confined to advanced liver disease but more commonly affect the cardiovascular system (4)(5)(6)(7)(8). Globally, 25-40% of NAFLD patients have cardiovascular diseases (CVDs), which is the leading cause of death in these individuals.…”

Section: Introductionmentioning

confidence: 99%

The prevalence of MAFLD and its association with atrial fibrillation in a nationwide health check-up population in China

et al. 2022

Self Cite

View full text Add to dashboard Cite

Background and aimsThe epidemiological characteristics of MAFLD and its relationship with atrial fibrillation (AF) are limited in China. Therefore, we explored the epidemiological characteristics of MAFLD from adults along with the association of MAFLD and 12-ECG diagnosed AF in a nationwide population from health check-up centers.MethodsThis observational study used cross-sectional and longitudinal studies with 2,083,984 subjects from 2009 to 2017. Age-, sex-, and regional-standardized prevalence of MAFLD was estimated. Latent class analysis (LCA) was used to identify subclusters of MAFLD. Multivariable logistic regression and mixed-effects Cox regression models were used to analyze the relationship between MAFLD and AF.ResultsThe prevalence of MAFLD increased from 22.75% to 35.58% during the study period, with higher rates in males and populations with high BMI or resided in northern regions. The MAFLD population was clustered into three classes with different metabolic features by LCA. Notably, a high proportion of MAFLD patients in all clusters had overweight and prediabetes or diabetes. The MAFLD was significantly associated with a higher risk of AF in the cross-sectional study and in the longitudinal study. In addition, the coexistence of prediabetes or diabetes had the largest impact on subsequent AF.ConclusionOur findings suggested a high prevalence of MAFLD and a high prevalence of other metabolic diseases in the MAFLD population, particularly overweight and glucose dysregulation. Moreover, MAFLD was associated with a significantly higher risk for existing and subsequent subclinical AF in the Chinese population.

show abstract

Section: Introductionmentioning

confidence: 99%

The prevalence of MAFLD and its association with atrial fibrillation in a nationwide health check-up population in China

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…44,45 Some mechanistic studies have reported that NAFLD may initiate and accelerate vascular injury through oxidative stress, low-grade inflammation, IR and lipid metabolism. [46][47][48] Therefore, the MAFLD associated with PAD may be due to the oxidative stress, IR and systematic inflammation. Moreover, liver inflammation may directly contribute to the development of some extrahepatic diseases, such as CVD or DM.…”

Section: Discussionmentioning

confidence: 99%

The Association Between Metabolic Dysfunction-Associated Fatty Liver Disease and Peripheral Arterial Disease in the Chinese Population

Song¹,

Liu²,

Lei³

et al. 2023

DMSO

Self Cite

View full text Add to dashboard Cite

Purpose Emerging evidence suggested that metabolic dysfunction-associated fatty liver disease (MAFLD) was significantly associated with atherosclerotic diseases. Atherosclerosis in the peripheral arteries is the most common cause of peripheral arterial disease (PAD), which has not been substantially controlled in the past. We aimed to investigate the association between MAFLD and PAD in the Chinese population. Patients and Methods This observational study covered 102,115 participants who underwent health checkups with detailed examinations for PAD and MAFLD. PAD was measured by ankle-brachial index, and MAFLD was diagnosed by abdominal ultrasound. The generalized linear mixed models and random-effects Cox proportional hazards models were used to analyze the relationship between MAFLD and PAD. Results The baseline characteristics showed that patients with MAFLD had higher prevalence of PAD compared with those without MAFLD (2.7% vs 2.2%). Compared to non-MAFLD, the individuals with MAFLD were associated with a higher risk of the presence of PAD (adjusted odds ratio: 1.30, 95% confidence interval (CI): 1.19–1.42, P < 0.001). In the prospective cohort study, 6833 participants underwent a follow-up of 2.76 (standard deviation: 1.36) years, and MAFLD at baseline was a higher risk of associated with incident PAD (adjusted hazards ratio: 1.67, 95% CI: 1.17–2.38, P = 0.005). Moreover, with the accumulation of metabolic abnormalities, the risk of the PAD was increased in the individuals with MAFLD. Furthermore, MAFLD attributed risk of PAD was more evident in participants without metabolic comorbidities. Conclusion MAFLD was associated with a significantly higher risk for the prevalence and incidence of PAD in the Chinese population. The finding suggested that individuals with MAFLD are not only have a higher risk of coronary heart diseases but also have an increased risk of atherosclerosis in peripheral arteries.

show abstract

“…Because metabolic syndrome is related to NAFLD, abnormal lipid metabolism is common in individuals with NAFLD and can increase the risk of CVD (115)(116)(117). Therefore, lipid-lowering strategies are critical for individuals with NAFLD.…”

Section: Statinsmentioning

confidence: 99%

Effects of treatment of non-alcoholic fatty liver disease on heart failure with preserved ejection fraction

Yang

Tian²,

Zhang³

et al. 2023

Front. Cardiovasc. Med.

Self Cite

View full text Add to dashboard Cite

In the past few decades, non-alcoholic fatty liver disease (NAFLD) and heart failure with preserved ejection fraction (HFpEF) have become the most common chronic liver disease and the main form of heart failure (HF), respectively. NAFLD is closely associated with HFpEF by sharing common risk factors and/or by boosting systemic inflammation, releasing other secretory factors, and having an expansion of epicardial adipose tissue (EAT). Therefore, the treatments of NAFLD may also affect the development and prognosis of HFpEF. However, no specific drugs for NAFLD have been approved by the Food and Drug Administration (FDA) and some non-specific treatments for NAFLD are applied in the clinic. Currently, the treatments of NAFLD can be divided into non-pharmacological and pharmacological treatments. Non-pharmacological treatments mainly include dietary intervention, weight loss by exercise, caloric restriction, and bariatric surgery. Pharmacological treatments mainly include administering statins, thiazolidinediones, glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter 2 inhibitors, and metformin. This review will mainly focus on analyzing how these treatments may affect the development and prognosis of HFpEF.

show abstract

NAFLD as a continuous driver in the whole spectrum of vascular disease

Cited by 23 publications

References 173 publications

The prevalence of MAFLD and its association with atrial fibrillation in a nationwide health check-up population in China

The prevalence of MAFLD and its association with atrial fibrillation in a nationwide health check-up population in China

The Association Between Metabolic Dysfunction-Associated Fatty Liver Disease and Peripheral Arterial Disease in the Chinese Population

Effects of treatment of non-alcoholic fatty liver disease on heart failure with preserved ejection fraction

Contact Info

Product

Resources

About